Actual Medication Pill Burden and Dosing Frequency in HIV-infected Patients with Undetectable Viral Loads

Abstract

Studies have shown equivalent or improved outcomes with once-daily antiretroviral (ARV) regimens, but have failed to quantify the true daily dosing frequency and pill burden of HIV-infected patients, by not considering concomitant medications. This study was conducted to describe the total daily number (pill burden) and dosing frequency for all oral medicines, and not just ARV medications in HIV-infected patients with undetectable viral loads.

Keywords

HIV once daily antiretroviral medications adherence outcomes co-morbidities

References

Haas DW , Zala C , Schrader S , et al. Therapy with atazanavir plus saquinavir in patients failing highly active antiretroviral therapy: A randomized comparative pilot trial. AIDS 2003;17:1339-1349.

Monno L , Cargnel A , Soranzo ML , et al. Comparison of once and twice daily dosing of didanosine in combination with stavudine for the treatment of HIV-1 infection. AI 454-146 Team. Antivir Ther 1999;4:195-202.

Cheer SM , Goa KL . Stavudine once daily. Drugs 2002;62:2667-2674.

Lopez-Cortes LF , Ruiz-Valderas R , Viciana P , et al. Once-daily saquinavir -sgc plus low-dose ritonavir (1200/100 mg) in combination with efavirenz: Pharmacokinetics and efficacy in HIV-infected patients with prior antiretroviral therapy. J Acquir Immune Defic Syndr 2003;32:240-242.

Cahn P. Emtricitabine: A new nucleoside analogue for once-daily antiretroviral therapy. Expert Opin Investig Drugs 2004;13:55-68.

Barreiro P , Garcia-Benayas T , Soriano V , Gallant J . Simplification of antiretroviral treatment—how to sustain success, reduce toxicity, and ensure adherence avoiding PI use. AIDS Rev 2002;4:233-241.

Jacobson JM , Israel RJ , Lowry I , et al. Treatment of advanced human immunodeficiency virus type 1 disease with the viral entry inhibitor PRO 542. Antimicrob Agents Chemother 2004;48:423-429.

Piliero PJ , Colagreco JP . Simplified regimens for treating HIV infection and AIDS. J Am Acad Nurse Pract 2003;15:305-312.

Yuen GJ , Lou Y , Bumgarner NF , et al. Equivalent steady-state pharmacokinetics of lamivudine in plasma and lamivudine triphosphate within cells following administration of lamivudine at 300 milligrams once daily and 150 milligrams twice daily. Antimicrob Agents Chemother 2004;48:176-182.

10.

Gallant JE , Block DS . Adherence to antiretroviral regimens in HIV-infected patients: Results of a survey among physicians and patients. J Int Assoc Physicians AIDS Care 1998;4:32-35.

11.

Taburet AM , Paci-Bonaventure S , Peytavin G , Molina JM . Once-daily administration of antiretrovirals: Pharmacokinetics of emerging therapies. Clin Pharmacokinet 2003;42:1179-1191.

12.

Stone VE , Hogan JW , Schuman P , et al. HERS Study. Antiretroviral regimen complexity, self-reported adherence, and HIV patients’ understanding of their regimens: A survey of women in the HER study. J Acquir Immune Defic Syndr 2001:28:124-131.

13.

Chesney M. Adherence to HAART regimens. AIDS Patient Care STDS 2003;17:169-177.

14.

Miller LG , Huffman HB , Weidmer BA , Hays RD . Patient preferences regarding antiretroviral therapy. Int J STD AIDS 2002;13:593-601.

15.

Cohen C , Elion RA , Frank I , et al. Once-daily antiretroviral therapies for HIV infection: Consensus Statement of an Advisory Committee of the International Association of Physicians in AIDS Care. J Int Assoc Physicians AIDS Care 2002;1:141-145.

16.

Fauci AS , Bartlett JG (Co-chairs). Panel on Clinical Practices for Treatment of HIV Infection . Department of Health and Human Services (DHHS) . Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. March 23, 2004. [cited 2004 May 3]. P. 20. Available from: http://AIDSinfo.nih.gov

17.

Eron JJ , Feinberg J , Kessler HA , et al. Once-daily versus twice-daily lopinavir/ritonavir in antiretroviral-naive HIV-positive patients: A 48-week randomized clinical trial. J Infect Dis 2004;189:265-272.

18.

Peterson AM , Takiya L , Finley R . Meta-analysis of trials of interventions to improve medication adherence. Am J Health Syst Pharm 2003; 60:657-665.

19.

Molina JM , Ferchal F , Rancinan C , et al. Once-daily combination therapy with emtricitabine, didanosine, and efavirenz in human immunodeficiency virus-infected patients. J Infect Dis 2000;182:599-602.

20.

Mole L , Schmidgall D , Holodniy M . A pilot trial of indinavir, ritonavir, didanosine, and lamivudine in a once-daily four-drug regimen for HIV infection. J Acquir Immune Defic Syndr 2001;27:260-265.

21.

Maggiolo F , Migliorino M , Maserati R , et al. Once Study Group. Virological and immunological responses to a once-a-day antiretroviral regimen with didanosine, lamivudine, and efavirenz. Antivir Ther 2001;6:249-253.

22.

Jordan WC , Jefferson R , Yemofio F , et al. Nevirapine plus efavirenz plus didanosine: A simple, safe, and effective once-daily regimen for patients with HIV infection. J Natl Med Assoc 2003;95:1152-1157.

23.

Maggiolo F , Ripamonti D , Gregis G , et al. Once-a-day therapy for HIV infection: A controlled, randomized study in antiretroviral-naive HIV-1-infected patients. Antivir Ther 2003;8:339-346.

24.

Cameron DW , Japour AJ , Xu Y , et al. Ritonavir and saquinavir in combination therapy for the treatment of HIV infection. AIDS 1999;13:213-224.

25.

Opravil M , Ledergerber B , Furrer H , et al. Swiss HIV Cohort Study. Clinical efficacy of early initiation of HAART in patients with asymptomatic HIV infection and CD4 count >350 x 106/I. AIDS 2002;16:1371-1381.

26.

Giorgi JV , Lyles RH , Matud JL , et al. Multicenter AIDS Cohort Study. Predictive value of immunologic and virologic markers after long or short duration of HIV- 1 infection. J Acquir Immune Defic Syndr 2002;29:346-355.

27.

Vanhems P , Hirschel B , Phillips AN , et al. Incubation time of acute human immunodeficiency virus (HIV) infection and duration of acute HIV infection are independent prognostic factors of progression to AIDS. J Infect Dis 2000;182:334-337.

28.

Shah SS , McGowan JP , Smith C , Blun S , Klein RS . Comorbid conditions, treatment, and health maintenance in older persons with human immunodeficiency virus infection in New York City. Clin Infect Dis 2002;35:1238-1243.

29.

Trotta MP , Ammassari A , Melzi S , et al. AdICoNA Study Group. Treatment-related factors and highly active antiretroviral therapy adherence. J Acquir Immune Defic Syndr 2002;31 Suppl 3:S128-S131.

30.

Orenstein R , Tsogas N . Looking beyond highly active antiretroviral therapy: Drug-related hepatotoxicity in patients with human immunodeficiency virus infection. Pharmacotherapy 2002;22:1468-1478.

31.

Heckman TG , Heckman BD , Kochman A , Sikkema KJ , Suhr J , Goodkin K . Psychological symptoms among persons 50 years of age and older living with HIV disease. Aging Ment Health 2002;6:121-128.

32.

Justice AC , Landefeld CD , Asch SM , Gifford AL , Whalen CC , Covinsky KE . Justification for a new cohort study of people aging with and without HIV infection. J Clin Epidemiol 2001;54 Suppl 1:S3-S8.

33.

Lewsey JD , Leyland AH , Murray GD , Boddy FA . Using routine data to complement and enhance the results of randomised controlled trials. Health Technol Assess 2000;4:1-55.

34.

Chesney MA . Factors affecting adherence to antiretroviral therapy. Clin Infect Dis 2000;30 Suppl 2:S171-S176.

35.

McDonald HP , Garg AX , Haynes RB . Interventions to enhance patient adherence to medication prescriptions: Scientific review. JAMA 2002;288:2868-2879.